Pfizer Inc. (NYSE:PFE) Shares Sold by Eagle Rock Investment Company LLC

Eagle Rock Investment Company LLC reduced its holdings in Pfizer Inc. (NYSE:PFE) by 58.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 117,972 shares of the biopharmaceutical company’s stock after selling 164,375 shares during the period. Eagle Rock Investment Company LLC’s holdings in Pfizer were worth $3,130,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the business. Bradley Foster & Sargent Inc. CT grew its holdings in Pfizer by 3.2% during the second quarter. Bradley Foster & Sargent Inc. CT now owns 271,120 shares of the biopharmaceutical company’s stock worth $7,586,000 after acquiring an additional 8,375 shares during the period. Mercer Global Advisors Inc. ADV boosted its position in Pfizer by 0.6% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 897,017 shares of the biopharmaceutical company’s stock worth $25,099,000 after purchasing an additional 5,246 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. grew its stake in shares of Pfizer by 1.4% during the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 190,811 shares of the biopharmaceutical company’s stock worth $5,339,000 after purchasing an additional 2,572 shares during the period. Blair William & Co. IL increased its holdings in shares of Pfizer by 85.9% during the 2nd quarter. Blair William & Co. IL now owns 1,953,310 shares of the biopharmaceutical company’s stock valued at $54,654,000 after purchasing an additional 902,376 shares in the last quarter. Finally, Sienna Gestion lifted its stake in shares of Pfizer by 0.8% in the 2nd quarter. Sienna Gestion now owns 221,295 shares of the biopharmaceutical company’s stock valued at $6,189,000 after purchasing an additional 1,771 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 1.1 %

PFE stock opened at $26.51 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a 50-day moving average of $26.11 and a two-hundred day moving average of $28.01. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a market cap of $150.20 billion, a price-to-earnings ratio of 35.82, a PEG ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.17) earnings per share. As a group, analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.49%. Pfizer’s payout ratio is presently 227.03%.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on PFE. Wolfe Research initiated coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Citigroup began coverage on shares of Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target on the stock. Bank of America reissued a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Finally, Sanford C. Bernstein began coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Insider Activity at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now owns 10,000 shares in the company, valued at $282,400. This represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is currently owned by insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.